The Nasdaq Biotechnology Index fell 3% in a single session. Fulcrum Therapeutics dropped 51%. Abivax ADR declined 44%. To someone unfamiliar with biotech investing, these numbers look like a sector-wide catastrophe. To someone who has followed biotech for any length of time, this pattern is distressingly familiar.

What Binary Risk Actually Means

Most biotechs are valued almost entirely on the probability-weighted expected value of their clinical pipeline. A company running a Phase 3 trial for a treatment with no approved alternatives can trade at a significant premium to its tangible assets because the market is pricing in the possibility of approval and the subsequent revenue.

When trial data is negative, that probability collapses toward zero in a single day. There is no gradual repricing. The event-driven nature of clinical results means that 50% single-day declines are not outliers. They are the expected outcome of a negative binary event. Fulcrum and Abivax both appear to have faced exactly this: clinical data that did not support the hypothesis the market had been pricing.

The Honest Question for Retail Investors

The problem is that individual retail investors typically do not have the scientific background to independently evaluate clinical trial design, primary endpoints, or statistical power. They are making probability bets on outcomes that require specialised knowledge to assess. When they win, it can be spectacular. When they lose, the math is unambiguous.

A more structured way to access biotech is through diversified ETFs like XBI or IBB, which spread single-trial risk across many positions. No single clinical failure produces a 50% portfolio drawdown. The return profile is lower, but the risk of a catastrophic single-name event is eliminated. For most individual investors, this is the more appropriate exposure.